2023 年 11 月 20 日

Calyx CTMS Select Delivers Robust Functionality for Small/Mid-sized Biopharma and CROs

Pre-configured, scalable trial management system enables quicker study starts at a lower cost

Nottingham, England and Billerica, MA – 2023 年 11 月 20 日 Calyx, the eClinical and eRegulatory solutions and services provider relied on for solving complex data challenges in clinical research announces an offering for small and mid-sized (SMID) biopharmaceutical companies and CROs that delivers the reliability and global operational support of a proven Clinical Trial Management System (CTMS) with faster implementation times and at lower costs.

Calyx CTMS Select is a scalable, pre-configured, and validated solution with the rich features required for effective clinical trial management oversight and monitoring. Based on Calyx’s 25+ years of expertise supporting diverse trials, it is perfectly tailored to meet the needs, timelines, and budgets of SMID organizations that don’t require CTMS customization.

“We listened closely to our customers in designing a robust CTMS solution that’s backed by Calyx’s global support team and enables SMID organizations to scale as their operations require,” said Serena Barker, Vice President and General Manager of Enterprise Technology at Calyx. “We’re delighted to extend our expertise on best practices to drive value for these organizations and to deliver a reliable CTMS that enables them to simplify the oversight of their trials at a lower cost than comparable solutions available today.”

Calyx CTMS Select can be implemented in as little as 6-8 weeks and includes out-of-the-box eTMF and EDC integrations and sophisticated features – such as comprehensive site payments – that are rarely included in solutions for smaller organizations.

Click here for more information on Calyx CTMS Select.

关于凯理斯

凯理斯是一家全球顶尖的医学影像及临床信息化管理供应商,提供包括独立中心影像评估(IRC)、随机化和药品供应管理系统及服务(IRT)、临床试验管理系统(CTMS) 、临床试验电子数据采集系统(EDC)、eCTD递交及临床法规信息系统(RIM)等全面解决方案。 凯理斯服务申办方和临床研究组织 (CRO)已经近三十年,支持多达 60,000 项试验,成功帮助申办方通过了 650 个新药审批,惠及1,800 万名患者。经过近10年在中国新药研发行业的深耕,凯理斯中国团队已逾百人;通过全面深入的本土化,目前已服务近120家本土企业,同时和国内近10家顶尖药企及创新药公司达成企业级长期战略合作。

CTMS | EDC | IRT | 医学影像 | RIM

Take your trials further with intelligent insights at Calyx.ai or at LinkedIn, Twitter, or Facebook.

联系人:

Christine Tobin | christine.tobin@calyx.ai | +1 412-628-8598


获取最新消息

不错过任何精彩内容。立即注册,接收涵盖行业新闻和其他相关信息的电子邮件,帮助您推进临床开发。

  • 此字段用于验证目的,应保持不变。
Powered by Translations.com GlobalLink OneLink Software